APIM Therapeutics (Norway)
The company targets a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy. ATX-101, our lead drug candidate has been tested in ovarian cancer (phase Ib) and sarcoma (phase II) patients. By exploiting a novel therapeutic target, our vision is to develop novel single agent & combinatorial cancer treatments with the potential to address serious unmet patient needs.
Basic Information
- Category: business
- Website: http://www.apimtherapeutics.com/
Documented Facts
- Email: contact@apimtherapeutics.com (No linked source recorded for this statement.)
Evidence and Sources
- APIM Therapeutics (Norway) — Official Site (official)
- APIM Therapeutics (Norway) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about APIM Therapeutics (Norway).
- Canonical profile: https://brandsource.ai/brands/apim-therapeutics-norway
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/apim-therapeutics-norway/json-ld
- Citation profile API: https://brandsource.ai/api/brands/apim-therapeutics-norway/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
The company targets a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy. ATX-101, our lead drug candidate has been tested in ovarian cancer (phase Ib) and sarcoma (phase II) patients. By exploiting a novel therapeutic target, our vision is to develop novel single agent & combinatorial cancer treatments with the potential to address serious unmet patient needs.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.